ESAs In Renal Disease: Risk/Benefit Differs With Disease Stage, Amgen Says

Medicare coverage policy for erythropoiesis-stimulating agents in patients with chronic kidney disease should recognize that the ESA needs of patients are very different for those who are on dialysis versus those who are not, Amgen said in recent comments to the Centers for Medicare and Medicaid Services